Gilbert S. Omenn - 16 Jan 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Reporting relationship
Director
Issuer ticker
GALT
Reported as of
16 Jan 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
21 Jan 2026, 16:46:12 UTC
Prior SEC filing
05 Jan 2026
Next SEC filing
10 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Jack W. Callicutt, by power of attorney

Key filing fact

Gilbert S. Omenn filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 21 Jan 2026.

Key facts

  • This page summarizes Gilbert S. Omenn's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 21 Jan 2026, 16:46.

Change

  • Previous filing in this sequence was filed on 05 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001184227 Primary reporting owner

OMENN GILBERT S

Relationship
Director
Address
4960 PEACHTREE INDUSTRIAL BLVD, SUITE 240, NORCROSS
Signature
Jack W. Callicutt, by power of attorney
Signature date
21 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GALT transaction Derivative

Stock option (right to buy)

Award

Transaction value
$0
Shares
+60,000
Change %
Price
$0.000000
Shares after
60,000
Date
16 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
60,000
Exercise price
$0.000000
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

Footnote F2

The options vest 100% on December 31, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .